Fig. 1From: RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapyAnalysis of the progression of disease-free survival probability among low, high and unknown groupsBack to article page